XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access
via the World Wide Web to its presentation at the 2014 Credit Suisse
Healthcare Conference in Phoenix, Arizona. The live presentation will
occur at 8:30 a.m. Pacific Time (9:30 a.m. Mountain Time) on Wednesday,
November 12, 2014. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets in the United States and developing its novel
fumaric acid ester product candidate, XP23829, as a potential treatment
for patients with moderate-to-severe chronic plaque-type psoriasis
and/or relapsing forms of multiple sclerosis. REGNITE® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by
Astellas Pharma Inc. XenoPort granted exclusive world-wide rights for
the development and commercialization of its clinical-stage oral product
candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals,
Inc. for all indications. XenoPort's pipeline of product candidates also
includes a potential treatment for patients with Parkinson's disease.
To learn more about XenoPort, please visit the Website at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort,
Inc.
XNPT2G
Copyright Business Wire 2014